Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study

BMC Neurology

Table 1 Demographic data and main variables for each patient

Patients	Age	Sex	Type of MS	Progression time (years) ^a	EDSS	Current treatment	WM lesion volume on FLAIR (mL)	DWM SUVRc	NAWM SUVRc	NAWM volume (mL)	Uptake changes in WM (%)
1	42	F	RR	3.5	3.5	Azathioprine	24.13	1.14	1.36	173.00	−16.04
2	42	F	RR	14	4.0	Fingolimod	51.83	1.21	1.27	131.80	−4.51
3	43	F	RR	12	4.0	Fingolimod	10.01	1.45	1.67	193.11	−12.98
4	44	F	RR	15	4.0	Natalizumab	58.30	1.37	1.57	149.43	−12.61
5	47	F	RR	12	3.5	Fingolimod	52.06	1.20	1.46	163.85	−17.60
6	41	M	SP	19	5.0	Fingolimod	47.49	1.41	1.61	155.32	−12.41
7	46	M	SP	17	5.0	Glatiramer acetate	19.23	1.25	1.60	186.48	−22.10
8	47	F	SP	16	5.0	Fingolimod	34.06	1.18	1.57	182.44	−24.47
9	48	M	SP	14	6.0	Teriflunamide	40.0	1.28	1.54	170.71	−17.11
10	50	M	SP	11	6.5	Azathioprine	45.60	1.09	1.45	178.60	−24.62
11	50	F	PP	14	6.0	Glatiramer acetate	8.58	1.31	1.70	189.53	−22.63
12	61	F	PP	11	6.5	None	16.69	1.07	1.40	157.32	−23.71
C-1	48	F	-	-	-	-	-			185.20	**
C-2	50	M	-	-	-	-	-			185.60	**
C-3	52	F	-	-	-	-	-			185.00	**

C Healthy control, DWM damaged white matter, EDSS expanded disability status scale, F female, M male, NAWM normally-appearing white matter;
PP primary-progressive, RR relapsing-remitting, SP secondary-progressive, SUVRc standardized uptake value relative to cerebellum, WM white matter
^aTime since onset is given in years from the first exacerbation or symptom
^aIn healthy controls, uptake change was estimated between total white matter and the mean of the uptake in the ROIs of DWM developed for the MS patients

ISSN: 1471-2377